{"id":4434,"date":"2020-08-26T09:20:23","date_gmt":"2020-08-26T09:20:23","guid":{"rendered":"https:\/\/clinlabint.3wstaging.nl\/proadm-proven-to-be-the-best-risk-predictor\/"},"modified":"2021-01-08T11:29:23","modified_gmt":"2021-01-08T11:29:23","slug":"proadm-proven-to-be-the-best-risk-predictor","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/proadm-proven-to-be-the-best-risk-predictor\/","title":{"rendered":"ProADM proven to be the best risk predictor"},"content":{"rendered":"
The new biomarker ProADM significantly improves risk assessment of patients suffering from lower respiratory tract infection (LRTI)<\/strong><\/p>\n An early risk assessment of LRTI patients is essential for optimizing treatment and rational resource allocation. Adrenomedullin (ADM) has a significant presence in the course of LRTI and is strongly associated with a patient\u2019s risk of mortality and severe complications. ADM reflects a patient\u2019s risk profile while its elevation is independent of the LRTI etiology. Features of ProADM (MR-proADM) measurement<\/strong> >> read more on www.thermoscientific.com\/ProAdrenomedullin<\/link><\/strong>
\nA robust method to assess ADM levels is the measurement of a stable surrogate marker, the mid-regional fragment of ProAdrenomedullin (MR-proADM). The only available automated immunoassay is from Thermo Fisher Scientific. <\/p>\n
\n\u2022 Directly reflective of ADM production in a 1:1 ratio
\n\u2022 Increased stability relative to ADM
\n\u2022 Reliably measurable with the automated Thermo Scientific B\u00b7R\u00b7A\u00b7H\u00b7M\u00b7S MR-proADM KRYPTOR immunoassay
\n\u2022 Well documented for clinical use
\n\u2022 Rapidly available to aid timely clinical decision-making (assay incubation time 29 minutes)
\n\u2022 Small sample volume (26\u00b5L)
\n\u2022 Measurement in EDTA plasma <\/p>\n
\n
\nSupplier:<\/strong> Thermo Fisher Scientific
\nWebsite:<\/strong> <\/a><\/p>\n